NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

The FDA approved Imfinzi with chemotherapy for neoadjuvant treatment in muscle invasive bladder cancer, followed by adjuvant Imfinzi post-cystectomy. The phase 3 NIAGARA trial demonstrated significant ...

Bill Russell and Jim Rieker are survivors. Both diagnosed with bladder cancer, the men have made it their mission to help others with the disease through the Bladder Cancer Advocacy Network, the ...

N1 Single lymph node metastasis, 2 cm or less in greatest dimension N1 Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac or presacral lymph node) N2 ...

In December 2025, Astellas Pharma and Pfizer reported that their Phase 3 EV-304 trial of PADCEV plus Keytruda in muscle-invasive bladder cancer achieved statistically significant improvements in event ...